Printer Friendly

SYNTEX ACQUIRES EXCLUSIVE RIGHTS TO MARKET ELAN'S ONCE-DAILY NAPROXEN FORMULATION IN UNITED STATES

 ATHLONE, Ireland, and PALO ALTO, Calif., March 17 /PR Newswire/ -- Elan Corp. plc. (AMEX: ELN), Drug Research Corp. (AMEX: ELR) and Syntex Corp. (NYSE: SYN) announced today that Syntex Pharmaceuticals International Ltd. (SPIL) has acquired the exclusive U.S. marketing rights to Elan's once-daily naproxen formulation.
 Elan's formulation, which has been developed under its license agreement with Drug Research Corp., a research organization closely affiliated with Elan Corp., is in the final stages of clinical trials in the United States, and the company expects to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) during the second half of calendar 1993. Neither company is forecasting the timing of marketing approval or launch. Syntex Laboratories Inc., Syntex's U.S. marketing organization, will sell the product following FDA marketing approval. No further details of the agreement were disclosed.
 The once-daily naproxen formulation uses Elan's IPDAS (Intestinal Protection Drug Absorption System), in which its specially coated particles of naproxen sodium are compressed into tablets and are diffused and slowly absorbed throughout the gastrointestinal tract. The naproxen delivered to the patient's bloodstream is the same active ingredient that is in Syntex's Naprosyn(R), the top-selling branded prescription medicine for arthritis pain and inflammation in the United States. Syntex discovered, developed, manufactures and markets naproxen in a variety of formulations worldwide.
 In commenting on the licensing agreement, Elan's Chairman and Chief Executive Officer Donald E. Panoz, stated that "he was pleased to have come to an agreement with Syntex to market the product in the United States. I believe their position as market leader among branded nonsteroidal anti-inflammatory medicines prescribed to treat arthritis pain and inflammation makes them an ideal marketing partner for Elan. In addition, Syntex Pharmaceuticals Ltd., Syntex's operating unit in the United Kingdom, launched once-daily naproxen, using Elan's technology, in February 1993. Syntex also has exclusive marketing rights for the product in Ireland."
 "We are particularly happy to announce this agreement," Paul E. Freiman, Syntex chairman and chief executive officer, said. "We think this product has the potential to fill an important need in the nonsteroidal anti-inflammatory marketplace."
 Elan Corp. plc. is a world leader in the specialized health-care field of advanced reformulations and drug delivery, concentrating on improved drug absorption and utilization. Elan operates research and manufacturing facilities in Athlone, Ireland; Gainesville, Ga.; Brea, Calif.; and Cambridge, Mass., in the United States; Enschede, Netherlands; Manila, Philippines; and Mezzovico, Switzerland. Currently 20 Elan products have received regulatory approval for marketing in one or more of 38 countries worldwide.
 Syntex Corp. is a multinational, research-based healthcare company dedicated to the discovery, development, manufacture and marketing of innovative, cost-effective prescription medicines. The company's products included medicines to treat pain and inflammation; allergies; cardiovascular, cerebrovascular, gynecologic, viral and skin diseases; and oral contraceptives. Syntex also discovers, develops, manufactures and markets animal pharmaceutical products and medical diagnostic systems.
 -0- 3/17/93
 /CONTACT: Linda Thomas of Syntex, 415-852-1321; or Donald E. Panoz, chairman and chief executive officer, or Brian Crotty, vice president of communications, of Elan, 212-688-6840/
 (ELM ELR SYN)


CO: Syntex Corp.; Elan Corp. plc; Drug Research Corp. ST: California IN: MTC SU:

GT -- SJ002 -- 6885 03/17/93 08:45 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 17, 1993
Words:533
Previous Article:79-YEAR-OLD RETIREE MAKES A FORTUNE ON HIS INVENTIONS
Next Article:FIRST UNION'S HUGH LONG TAPPED FOR WASHINGTON, D.C. EXECUTIVE POST; CHARLES WALKER RETURNS TO AUGUSTA
Topics:


Related Articles
ELAN'S ONCE-DAILY FORMULATION OF NAPROXEN LICENSED TO SYNTEX IN THE U.K.
SYNTEX ACQUIRES EXCLUSIVE RIGHTS TO MARKET ELAN'S ONCE-DAILY NAPROXEN FORMULATION IN UNITED STATES
FDA UPDATES ADVISORY COMMITTEES ON OTC NAPROXEN; LABELING DISCUSSIONS WITH FDA CONTINUE
AGREEMENT FOR SYNTEX TO MARKET ELAN'S ONCE-DAILY NAPROXEN FORMULATION IN U.S. ENDS; DISCUSSIONS WILL CONTINUE
SYNTEX MEETING HIGHLIGHTS NEW DRUG PIPELINE, RECENT PRODUCT APPROVAL
SYNTEX REPORTS SECOND QUARTER EPS DOWN 20 PERCENT TO $.43
SYNTEX AND ELAN CORPORATION SIGN AGREEMENT FOR MARKETING OF ONCE-DAILY FORMULATION OF NAPROXEN
SYNTEX AND ELAN CORPORATION SIGN AGREEMENT FOR MARKETING OF ONCE-DAILY FORMULATION OF NAPROXEN
SYNTEX RECEIVES CLEARANCE FOR ENTERIC-COATED EC-NAPROSYN(TM) IN THE UNITED STATES
Elan and Scherer Announce License for Zydis Formulation

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters